Patents Examined by Sun Jae Yoo
-
Patent number: 11918584Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.Type: GrantFiled: July 21, 2022Date of Patent: March 5, 2024Assignee: Amgen Inc.Inventors: James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
-
Patent number: 11919884Abstract: A method for preparing voriconazole L-camphorsulphonate and voriconazole. The method for preparing voriconazole L-camphorsulphonate comprises: method 1: dissolving (2R,3S)/(2S,3R) isomer mixture and L-camphor sulphonic acid in water and acetone, and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate; method 2: (a) dissolving a mixture of isomer mixture and L-camphor sulphonic acid in a first solvent and then performing crystallisation filtration; or (a?) dissolving L-camphorsulphonate of the isomer mixture in a first solvent and then performing crystallisation filtration; (b) concentrating the filtrate obtained in step (a) or (a?) into a solid; and (c) dissolving the solid obtained in step (b) in a second solvent and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate. Adjusting the resolution solvent effectively reduces production costs and facilitates recycling of the resolution solvent.Type: GrantFiled: November 10, 2016Date of Patent: March 5, 2024Assignee: Zhejiang Huahai Pharmaceutical Co., Ltd.Inventors: Hu Huang, Wenfeng Huang, Guoliang Tu, Zhongming Xu, Qianghui Wu, Zhaoyang Meng, Yuling Fang
-
Patent number: 11911376Abstract: Methods of treating, reducing the risk of, preventing, or alleviating at least one symptom of a retinal disease, injury, or condition in a subject involve administering a pharmaceutically effective amount of kynurenic acid to the subject. The kynurenic acid may be administered intravenously or intravitreally. Systems for treating retinal diseases, injuries, or conditions are also disclosed and may include an administration device.Type: GrantFiled: March 12, 2021Date of Patent: February 27, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Ram H. Nagaraj, Rooban B. Nahomi, Mi-hyun Nam
-
Patent number: 11903907Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.Type: GrantFiled: July 17, 2020Date of Patent: February 20, 2024Assignees: TAIPEI MEDICAL UNIVERSITY, CATHAY GENERAL HOSPITALInventors: Joen-Rong Sheu, Fa-Kung Lee, Chih-Cheng Chien, Chih-Ming Ho, Chao-Chien Chang, Cheng-Ying Hsieh, Jing-Ping Liou
-
Patent number: 11903945Abstract: Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication.Type: GrantFiled: December 11, 2020Date of Patent: February 20, 2024Assignee: Corcept Therapeutics IncorporatedInventors: Ada Lee, Joseph Belanoff, Hazel Hunt
-
Patent number: 11905248Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: GrantFiled: October 15, 2019Date of Patent: February 20, 2024Assignee: CALCIMEDICA, INC.Inventors: Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Patent number: 11897848Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: GrantFiled: June 4, 2021Date of Patent: February 13, 2024Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Patent number: 11897867Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):Type: GrantFiled: August 2, 2018Date of Patent: February 13, 2024Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.Inventors: Manuel Ellermann, Timothy Lewis
-
Patent number: 11891383Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.Type: GrantFiled: September 27, 2022Date of Patent: February 6, 2024Assignee: KEZAR LIFE SCIENCESInventors: Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
-
Patent number: 11883517Abstract: An external dermal composition and a method for beautifying skin are provided. The external dermal composition mainly includes a double nitrosyl-iron complex and a pharmaceutically acceptable additive. The external dermal composition delivers nitric oxide to a user's skin to beautify the skin when applied to the user's skin.Type: GrantFiled: January 10, 2022Date of Patent: January 30, 2024Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Tsai-Te Lu, Chieh-Cheng Huang, Han Chiu, Wei-Ping Wang, Ruei-Ting Wang, Yi-Cian Lai
-
Patent number: 11878029Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.Type: GrantFiled: January 4, 2021Date of Patent: January 23, 2024Assignee: FRED HUTCHINSON CANCER CENTERInventors: Richard A. Zager, Ali C M Johnson
-
Patent number: 11866401Abstract: A salicyl fumarate derivative having the general structural formula (A): In the structural formula (A), R1 is one of H+, Na+, K+or NH4+. R2 is one of fumaric acid ester products. The derivative has the general structural formula of the combination of salicylic acid and fumaric acid through an esterification reaction. This category of compounds possesses good effects in treatment of neurodegenerative diseases.Type: GrantFiled: November 27, 2020Date of Patent: January 9, 2024Assignee: CHONGQING NEUROPARK BIOSCIENCE CO., LTD.Inventors: Lichuan Yang, Bobby Thomas, Mingyue Guo
-
Patent number: 11857638Abstract: Conjugates comprise a drug or probe, a cell binding agent, and a quinone-containing linker. The quinone-containing linker may be reduced intracellularly to trigger release of the drug or probe. These conjugates may selectively deliver a drug or probe to a site of action of interest for local release of the active drug or probe.Type: GrantFiled: July 26, 2019Date of Patent: January 2, 2024Assignee: PROMEGA CORPORATIONInventors: Wenhui Zhou, Hui Wang, James J. Cali, Sarah Duellman, Jolanta Vidugiriene, Natasha Karassina
-
Patent number: 11845740Abstract: The invention relates to chemistry of organic substances, pharmacology and medicine, and concerns treating diseases associated and with aberrant activity of cells of the immune system, more particularly for treating lung, respiratory tract and abdominal diseases, radiation sickness and pain syndrome, and also other diseases by using compounds of formula (A) wherein R1 is —C(O)—R2—(O)— or —R2—C(O)— group, where R2 is —(CH2)n-group optionally substituted with one or two C1-C6 alkyls, or phenyl, n is an integer from 0 to 4; wherein compounds are selected from the group consisting of the group of compounds as set out in the description. These compounds, as well as pharmaceutically acceptable salts thereof, are highly effective in inhibiting glutaminyl cyclase, which is involved, in particular, in processes of post-translational modification of chemokines and chemotaxis of monocytes, macrophages and other cells of the immune system.Type: GrantFiled: May 24, 2018Date of Patent: December 19, 2023Assignees: LTD “VALENTA-INTELLEKT”Inventors: Vladimir Evgenievich Nebolsin, Anastasia Vladimirovna Rydlovskaya, Tatyana Alexandrovna Kromova
-
Patent number: 11844794Abstract: The invention provides (+)-?-dihydrotetrabenazine succinate salt. Also provided are (+)-?-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-?-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-?-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome. The invention further provides a method for preparing the (+)-?-dihydrotetrabenazine succinate salt.Type: GrantFiled: July 26, 2021Date of Patent: December 19, 2023Assignee: ADEPTIO PHARMACEUTICALS LIMITEDInventors: Andrew John Duffield, Anant Pandya
-
Patent number: 11840504Abstract: The present invention discloses a method for preparing a perfluoroalkyl sulfinate ester. The method includes reacting an ?-carbonyldiazo compound and a sodium perfluoroalkyl sulfinate, in an organic solvent, in the presence of anhydrous copper acetate as an optimal catalyst and tert-butyl hydroperoxide (TBHP) as a green oxidant, to obtain the perfluoroalkyl sulfinate ester. Compared to the prior art, the present method has the advantages of a wide range of reaction substrates, a short reaction time, a high reaction yield, and mild reaction conditions. The reaction does not require pre-activation of sodium perfluoroalkyl sulfinate, which can participate in the reaction directly, making reaction operations simple. The present method uses TBHP as a green oxidant and produces tert-butanol and water after reaction. Moreover, the present method avoids using a bromide or a chloride as a reaction material, and thus avoids formation of a large amount of a halide salt.Type: GrantFiled: March 18, 2021Date of Patent: December 12, 2023Assignee: SOOCHOW UNIVERSITYInventors: Xiaobing Wan, Hanghang Wang
-
Patent number: 11834444Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: July 6, 2017Date of Patent: December 5, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston, Timothy Claude Barden, Wayne C. Schairer
-
Patent number: 11834459Abstract: A compound of Formula I wherein X1 and X2 are independently CRX or N, and at least one of X1 or X2 is CRX; Y is selected from the group consisting of O, S, Se, NR?, BR?, CR?R?, and SiR?R?; R?, and R? are each independently selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, and combinations thereof; R is selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; RA, and RC each independently represent mono to the maximum allowable substitution, or no substitution; and each RX, RA, and RC is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, siType: GrantFiled: November 13, 2019Date of Patent: December 5, 2023Assignee: Universal Display CorporationInventors: Tyler Fleetham, Peter Wolohan, Hsiao-Fan Chen
-
Patent number: 11827661Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L3, L4, L6, L7, L8, M1, M2, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.Type: GrantFiled: February 26, 2016Date of Patent: November 28, 2023Assignee: Sony Group CorporationInventors: C. Frederick Battrell, Kenneth Farber, John C. Kumer, Tracy Matray, Michael VanBrunt
-
Patent number: 11827639Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.Type: GrantFiled: June 28, 2018Date of Patent: November 28, 2023Assignees: GENENTECH, INC., NEWLINK GENETICS CORPORATIONInventors: Zhonghua Pei, Brendan Parr, Wendy Liu, Richard Pastor, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Hima Potturi, Guoshen Wu, Xingyu Lin, Yanyan Chu, Powai Yuen